Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group

References

Page 1

	Year	Citations
Regression Models and Life-Tables D. R. Cox Journal of the Royal Statistical Society Series B (Statistical Methodology) Regression ModelsReliability EngineeringConditional LikelihoodEngineeringLife Prediction	1972	38.8K
Reporting results of cancer treatment A. B. Miller, Barth Hoogstraten, M. Staquet, Cancer World Health OrganizationMedicineCancer ManagementClinical EndpointOutcomes Research	1981	7.8K
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Patrick J. Loehrer, Lawrence H. Einhorn, Paul Elson, Journal of Clinical Oncology	1992	984
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse Cora N. Sternberg, Alan Yagoda, Howard I. Scher, Cancer	1989	673
M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium Cora N. Sternberg, Alan Yagoda, Howard I. Scher, The Journal of Urology	1988	627
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. C. Logothetis, F. H. Dexeus, Laura Finn, Journal of Clinical Oncology Urological ResearchUrologyGenitourinary CancerMvac-treated PatientsMvac Chemotherapy	1990	616
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Scott Saxman, Kathleen J. Propert, Lawrence H. Einhorn, Journal of Clinical Oncology	1997	496
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. John A. McCaffrey, S Hilton, Madhu Mazumdar, Journal of Clinical Oncology	1997	375
Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. Bruce J. Roth, Robert Dreicer, Lawrence H. Einhorn, Journal of Clinical Oncology	1994	325
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. Malcolm J. Moore, David Osoba, Keefe Murphy, Journal of Clinical Oncology	1994	165

Page 1